Targeting CGRP: Emerging Solutions in Migraine

Targeting CGRP: Emerging Solutions in Migraine

Program Overview1
In light of the evidence regarding the tremendous burden of migraine, leaders in the headache field have called for increased awareness of the availability of preventive efforts.

Dr. Diamond and Dr. Green will engage you in a lively discussion and presentation outlining the current landscape of chronic migraine including future thoughts on acute and preventative treatment. Our experts will share exciting data on new targets under development which have the potential to change the landscape of treatment in the future.

Participate in this interactive and forward-thinking activity to make sure you are prepared and “in the know” on the current and ongoing clinical trials targeting calcitonin gene-related peptide (CGRP) and their impact on the current unmet need in the treatment options for preventive treatment in migraine.

Learning Objectives
After completing this activity, the participant should be better able to:

  • Summarize the current landscape in the management and treatment of chronic migraine
  • Identify emerging therapies targeting CGRP in the treatment of migraine
  • Demonstrate knowledge of the role of the neuropeptide CGRP as a therapeutic target in the treatment of migraine
  • Summarize the current efficacy and safety data of CGRP monoclonal antibodies from clinical trials and their relation to other treatment options for the prevention of migraine headaches

Faculty/Planning Committee

Merle L. Diamond, MD
President, Managing Director
Diamond Headache Clinic
Chicago, Illinois

Mark W. Green, MD, FAAN
Director, Headache and Pain Medicine
Professor of Neurology, Anesthesiology, and Rehabilitation Medicine
Mount Sinai School of Medicine
New York, New York

Release/Expiration Dates
Release Date: December 28, 2016
Expiration Date: December 28, 2017


Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-16-133-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.


Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 16-133-048

Activity provided by MediCom Worldwide, Inc.

Published on Primary Issues, 1/24/2017

Participant will be leaving Primary Issues and completing this activity on the hosts website (Emerging Solutions in Pain).


0 Comment

Would you like to join the discussion? Feel free to contribute!

Write a Reply or Comment

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

‘Tis the Season: Re… January 9, 2017 An Influenza-like Ill… February 16, 2017